Literature DB >> 11716175

Increased detection of interleukin-5 in sputum by addition of protease inhibitors.

M M Kelly1, R Leigh, S Carruthers, P Horsewood, G J Gleich, F E Hargreave, G Cox.   

Abstract

The measurement of interleukin (IL)-5 in sputum is problematic, with interfering factors affecting immunoassay. The authors investigated whether sputum proteases could be acting as interfering factors by studying the effect of protease inhibitors (PI) on sputum IL-5 measurement. Induced sputa from 20 subjects with asthma were divided into aliquots, processed with and without protease inhibitors (in low and high concentrations) and the levels of IL-5 (spiked and endogenous) measured by enzyme immunoassay were compared. The concentration of sputum IL-5 was significantly increased by PI, with median (interquartile range) levels processed with no, low and high PI concentrations being 0 (0), 41.8 (75.6) and 66.1 (124.4) pg x mL(-1), respectively. There was also a significant increase in percentage recovery of spiked IL-5. Although high concentrations of PI reduced cell viability, there was no effect on total or differential cell counts and low concentrations of PI had no effect on cell counts or viability. Levels of endogenous interleukin-5 in sputum of asthmatic subjects can be significantly increased by the addition of protease inhibitors, and samples which would be regarded as negative for interleukin-5 without protease inhibitors may instead have considerable amounts of interleukin-5 detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716175     DOI: 10.1183/09031936.01.00098501

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Increases in airway eosinophilia and a th1 cytokine during the chronic asymptomatic phase of asthma.

Authors:  Chang Keun Kim; Jungi Choi; Zak Callaway; Koji Iijima; Gerald Volcheck; Hirohito Kita
Journal:  Respir Med       Date:  2010-08-14       Impact factor: 3.415

2.  Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Natalia Argel; Fadi Asfour; Perry S Brown; Barbara A Chatfield; Cori L Daines; Dixie Durham; Jessica A Francis; Barbara Glover; Theresa Heynekamp; John R Hoidal; Judy L Jensen; Ruth Keogh; Carol M Kopecky; Noah Lechtzin; Yanping Li; Jerimiah Lysinger; Osmara Molina; Craig Nakamura; Kristyn A Packer; Katie R Poch; Alexandra L Quittner; Peggy Radford; Abby J Redway; Scott D Sagel; Shawna Sprandel; Jennifer L Taylor-Cousar; Jane B Vroom; Ryan Yoshikawa; John P Clancy; J Stuart Elborn; Kenneth N Olivier; David R Cox
Journal:  BMC Med Res Methodol       Date:  2019-04-26       Impact factor: 4.615

3.  Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD.

Authors:  M Bafadhel; S Saha; R Siva; M McCormick; W Monteiro; P Rugman; P Dodson; I D Pavord; P Newbold; C E Brightling
Journal:  Respiration       Date:  2009-05-27       Impact factor: 3.580

4.  Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Ruth H Keogh; Yanping Li; Judy L Jensen; William Walsh; Kristyn Packer; Teresa Clark; Holly Carveth; Jun Chen; Shaunessy L Rogers; Christen Lane; James Moore; Anne Sturrock; Robert Paine; David R Cox; John R Hoidal
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.